Petition Against Increlex Approval Not "Compelling" – Agency Review
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Insmed's contention that Tercica's orphan drug Increlex lacked an adequate safety database to justify approval was contradicted by the "very large" amount of data relative to the size of the target population, according to Office of Drug Evaluation II Director Robert Meyer, MD
You may also be interested in...
Tercica Increlex Hypoglycemia Risk Mitigated By Dose Timing, Titration – FDA
FDA concerns over Tercica’s Increlex hypoglycemic seizure risk led to strengthened labeling on the need for dosing at meal time but were insufficient to warrant rejection of the extreme short stature therapy, agency review documents show.
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011